Notice of Meeting, 71582-71583 [2023-22797]

Download as PDF 71582 Federal Register / Vol. 88, No. 199 / Tuesday, October 17, 2023 / Notices Date: November 16–17, 2023. Time: 9:30 a.m. to 7:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Joonil Seog, SCD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–402–9791, joonil.seog@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Computational, Modeling, and Biodata Management. Date: November 16, 2023. Time: 10:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Marie-Jose Belanger, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm 6188, MSC 7804, Bethesda, MD 20892, 301–435–1267, belangerm@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: October 12, 2023. Victoria E. Townsend, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2023–22859 Filed 10–16–23; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health lotter on DSK11XQN23PROD with NOTICES1 National Center for Advancing Translational Sciences; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center for Advancing Translational Sciences Special VerDate Sep<11>2014 17:02 Oct 16, 2023 Jkt 262001 Emphasis Panel; Botulinum Toxin Potency Assay using Tissue Chips. Date: November 20, 2023. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Center for Advancing Translational Sciences, National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Rahat (Rani) Khan, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1078, Bethesda, MD 20892, 301–594–7319, khanr2@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS) Dated: October 12, 2023. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2023–22858 Filed 10–16–23; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Mental Health Special Emphasis Panel; BRAIN Initiative: Centers for Engineering Molecular Technologies for Functional Dissection of Neural Circuits (UM1). Date: November 17, 2023. Time: 10:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Jasenka Borzan, Ph.D., Scientific Review Officer, Division of PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 Extramural Activities, National Institute of Mental Health, National Institutes of Health, 6001 Executive Blvd., Neuroscience Center, Bethesda, MD 20892, 301–435–1260, jasenka.borzan@nih.gov. (Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS) Dated: October 11, 2023. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2023–22804 Filed 10–16–23; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Notice of Meeting Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention’s (CSAP) Drug Testing Advisory Board (DTAB) will convene via web conference on December 5, 2023, from 10 a.m. EST to 4:30 p.m. The board will meet in open-session December 5, 2023, from 10 a.m. EST to 4:30 p.m. EST to hear Federal Partner updates and presentations regarding NLCP activities, updates to the MRO manuals, lab created cannabinoids and other contaminants in commercially available products and the process for adding or removing analytes from the analyte table for federally regulated testing. The board will discuss the Mandatory Guidelines for Federal Workplace Drug Testing Programs and updates to the analyte table to include Fentanyl. Additionally the Department is asking for public comments on the recommendation of adding fentanyl/ nor-fentanyl to the analyte table. Section 8105 of the Fighting Opioid Abuse in Transportation Act, included in the SUPPORT for Patients and Communities Act, required the Secretary to determine whether it is justified, based on the reliability and cost-effectiveness of testing, to revise the Mandatory Guidelines for Federal Workplace Drug Testing Programs to include fentanyl. Section 8105 additionally required the Secretary to consider whether to include any other drugs or other substances listed in Schedule I and II of Controlled Substances Act (CSA). Norfentanyl is a metabolite of fentanyl. Because it is also an immediate precursor used in the illicit manufacture of fentanyl, it is a Schedule II substance under the CSA. E:\FR\FM\17OCN1.SGM 17OCN1 Federal Register / Vol. 88, No. 199 / Tuesday, October 17, 2023 / Notices Fentanyl accounts for a large proportion of overdose deaths in the United States and is therefore an important public safety concern. Furthermore, fentanyl is increasingly used as a stand-alone substance of abuse, not in conjunction with heroin and other substances. According to the National Forensic Laboratory Information System (NFLIS) 2021 report, fentanyl was the 4th most frequently identified drug and accounted for 11.61% of all drugs reported by forensic laboratories.1 Norfentanyl is an important component of identifying fentanyl users when urine is the specimen matrix. Fentanyl has been detected in oral fluid in pain management patients, overdose cases, and driving under the influence of drugs (DUID) cases. Information provided by HHS-certified laboratories in 2023 indicated that a majority (84%) of the laboratories analyzed non-regulated workplace specimens for fentanyl and/ or norfentanyl, and that all had the ability to analyze urine specimens for fentanyl with sufficiently sensitive detection limits using commercially available immunoassay kits and confirmatory test instrumentation commonly used in HHS-certified laboratories. The Division of Workplace Programs welcomes public comment prior to the DTAB meeting regarding the possible addition of Fentanyl to the Urine and Oral Fluid Analyte Table. Please see below for the process to submit comments. Addition to HHS Drug Testing Panels as listed below: Committee Name: Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Prevention, Drug Testing Advisory Board. Dates/Time/Type: December 5, 2023, from 10 a.m. EST to 4:30 p.m. EST: OPEN. Place: Virtual. To Submit Comments: Requests to make public comment during the public comment period of the December DTAB meeting must be made in writing at least 7 days prior to the meeting to the following email: DFWP@ samhsa.hhs.gov. Please submit written comments regarding the addition of Fentanyl to the analyte table to the following email: DFWP@samhsa.hhs.gov. Comments regarding the addition of Fentanyl to the analyte table will be accepted for review for an additional 30 days following this meeting, or no later than January 4th, 2024. Contact: Lisa S. Davis, M.S., Social Science Analyst, Center for Substance Abuse Prevention, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone: (240) 276–1440, Email: Lisa.Davis@ samhsa.hhs.gov. Anastasia Flanagan, Public Health Advisor, Division of Workplace Programs. [FR Doc. 2023–22797 Filed 10–16–23; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HOMELAND SECURITY U.S. Customs and Border Protection Initial test cutoff lotter on DSK11XQN23PROD with NOTICES1 Urine Analyte: Fentanyl ............ Norfentanyl ........ Oral Fluid Analyte: Fentanyl ............ Confirmation cutoff 1 ng/mL 1 ng/mL Agency Information Collection Activities; Extension of Existing 0.5 ng/mL. Collection; Crew Member’s Declaration 0.5 ng/mL. CBP (Form 5129) 1 ng/mL 0.5 ng/mL. Meeting registration information can be completed at https://snacregister. samhsa.gov/. Web conference and call information will be sent after completing registration. Meeting information and a roster of DTAB members may be obtained by accessing the SAMHSA Advisory Committees website, https://www.samhsa.gov/ about-us/advisory-councils/meetings, or by contacting the Designated Federal Officer, Lisa Davis. 1 National Forensic Laboratory Information System (NFLIS). (2021). NFLIS-Drug 2021 Annual Report. U.S. Department of Justice, Drug Enforcement Agency, Diversion Control Division. https://www.nflis.deadiversion.usdoj.gov/. VerDate Sep<11>2014 [OMB Control Number 1651–0021] 17:02 Oct 16, 2023 Jkt 262001 U.S. Customs and Border Protection (CBP), Department of Homeland Security. ACTION: 60-Day notice and request for comments. AGENCY: The Department of Homeland Security, U.S. Customs and Border Protection (CBP) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). The information collection is published in the Federal Register to obtain comments from the public and affected agencies. DATES: Comments are encouraged and must be submitted (no later than SUMMARY: PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 71583 December 18, 2023) to be assured of consideration. Written comments and/or suggestions regarding the item(s) contained in this notice must include the OMB Control Number 1651–0021 in the subject line and the agency name. Please use the following method to submit comments: Email. Submit comments to: CBP_ PRA@cbp.dhs.gov. ADDRESSES: FOR FURTHER INFORMATION CONTACT: Requests for additional PRA information should be directed to Seth Renkema, Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection, Office of Trade, Regulations and Rulings, 90 K Street NE, 10th Floor, Washington, DC 20229–1177, telephone number 202–325–0056 or via email CBP_PRA@cbp.dhs.gov. Please note that the contact information provided here is solely for questions regarding this notice. Individuals seeking information about other CBP programs should contact the CBP National Customer Service Center at 877–227–5511, (TTY) 1–800–877–8339, or CBP website at https://www.cbp.gov/. CBP invites the general public and other Federal agencies to comment on the proposed and/or continuing information collections pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.). This process is conducted in accordance with 5 CFR 1320.8. Written comments and suggestions from the public and affected agencies should address one or more of the following four points: (1) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) suggestions to enhance the quality, utility, and clarity of the information to be collected; and (4) suggestions to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. The comments that are submitted will be summarized and included in the request for approval. All comments will become a matter of public record. SUPPLEMENTARY INFORMATION: E:\FR\FM\17OCN1.SGM 17OCN1

Agencies

[Federal Register Volume 88, Number 199 (Tuesday, October 17, 2023)]
[Notices]
[Pages 71582-71583]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-22797]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Notice of Meeting

    Pursuant to Public Law 92-463, notice is hereby given that the 
Substance Abuse and Mental Health Services Administration's (SAMHSA) 
Center for Substance Abuse Prevention's (CSAP) Drug Testing Advisory 
Board (DTAB) will convene via web conference on December 5, 2023, from 
10 a.m. EST to 4:30 p.m.
    The board will meet in open-session December 5, 2023, from 10 a.m. 
EST to 4:30 p.m. EST to hear Federal Partner updates and presentations 
regarding NLCP activities, updates to the MRO manuals, lab created 
cannabinoids and other contaminants in commercially available products 
and the process for adding or removing analytes from the analyte table 
for federally regulated testing. The board will discuss the Mandatory 
Guidelines for Federal Workplace Drug Testing Programs and updates to 
the analyte table to include Fentanyl. Additionally the Department is 
asking for public comments on the recommendation of adding fentanyl/
nor-fentanyl to the analyte table.
    Section 8105 of the Fighting Opioid Abuse in Transportation Act, 
included in the SUPPORT for Patients and Communities Act, required the 
Secretary to determine whether it is justified, based on the 
reliability and cost-effectiveness of testing, to revise the Mandatory 
Guidelines for Federal Workplace Drug Testing Programs to include 
fentanyl. Section 8105 additionally required the Secretary to consider 
whether to include any other drugs or other substances listed in 
Schedule I and II of Controlled Substances Act (CSA). Norfentanyl is a 
metabolite of fentanyl. Because it is also an immediate precursor used 
in the illicit manufacture of fentanyl, it is a Schedule II substance 
under the CSA.

[[Page 71583]]

    Fentanyl accounts for a large proportion of overdose deaths in the 
United States and is therefore an important public safety concern. 
Furthermore, fentanyl is increasingly used as a stand-alone substance 
of abuse, not in conjunction with heroin and other substances. 
According to the National Forensic Laboratory Information System 
(NFLIS) 2021 report, fentanyl was the 4th most frequently identified 
drug and accounted for 11.61% of all drugs reported by forensic 
laboratories.\1\ Norfentanyl is an important component of identifying 
fentanyl users when urine is the specimen matrix. Fentanyl has been 
detected in oral fluid in pain management patients, overdose cases, and 
driving under the influence of drugs (DUID) cases. Information provided 
by HHS-certified laboratories in 2023 indicated that a majority (84%) 
of the laboratories analyzed non-regulated workplace specimens for 
fentanyl and/or norfentanyl, and that all had the ability to analyze 
urine specimens for fentanyl with sufficiently sensitive detection 
limits using commercially available immunoassay kits and confirmatory 
test instrumentation commonly used in HHS-certified laboratories.
---------------------------------------------------------------------------

    \1\ National Forensic Laboratory Information System (NFLIS). 
(2021). NFLIS-Drug 2021 Annual Report. U.S. Department of Justice, 
Drug Enforcement Agency, Diversion Control Division. https://www.nflis.deadiversion.usdoj.gov/.
---------------------------------------------------------------------------

    The Division of Workplace Programs welcomes public comment prior to 
the DTAB meeting regarding the possible addition of Fentanyl to the 
Urine and Oral Fluid Analyte Table. Please see below for the process to 
submit comments.
    Addition to HHS Drug Testing Panels as listed below:

------------------------------------------------------------------------
                                                   Initial
                                                    test    Confirmation
                                                   cutoff      cutoff
------------------------------------------------------------------------
Urine Analyte:
  Fentanyl......................................   1 ng/mL    0.5 ng/mL.
  Norfentanyl...................................   1 ng/mL    0.5 ng/mL.
Oral Fluid Analyte:
  Fentanyl......................................   1 ng/mL    0.5 ng/mL.
------------------------------------------------------------------------

    Meeting registration information can be completed at https://snacregister.samhsa.gov/. Web conference and call information will be 
sent after completing registration. Meeting information and a roster of 
DTAB members may be obtained by accessing the SAMHSA Advisory 
Committees website, https://www.samhsa.gov/about-us/advisory-councils/meetings, or by contacting the Designated Federal Officer, Lisa Davis.
    Committee Name: Substance Abuse and Mental Health Services 
Administration, Center for Substance Abuse Prevention, Drug Testing 
Advisory Board.
    Dates/Time/Type: December 5, 2023, from 10 a.m. EST to 4:30 p.m. 
EST: OPEN.
    Place: Virtual.
    To Submit Comments: Requests to make public comment during the 
public comment period of the December DTAB meeting must be made in 
writing at least 7 days prior to the meeting to the following email: 
[email protected].
    Please submit written comments regarding the addition of Fentanyl 
to the analyte table to the following email: [email protected].
    Comments regarding the addition of Fentanyl to the analyte table 
will be accepted for review for an additional 30 days following this 
meeting, or no later than January 4th, 2024.
    Contact: Lisa S. Davis, M.S., Social Science Analyst, Center for 
Substance Abuse Prevention, 5600 Fishers Lane, Rockville, Maryland 
20857, Telephone: (240) 276-1440, Email: [email protected].

Anastasia Flanagan,
Public Health Advisor, Division of Workplace Programs.
[FR Doc. 2023-22797 Filed 10-16-23; 8:45 am]
BILLING CODE 4162-20-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.